Search

Displaying results 1701 - 1710 of 4301 in total
  1. Drug

    Hydroxychloroquine

    go.drugbank.com/drugs/DB01611
    ApprovedInvestigational

    Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis...

  2. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  3. Drug

    Chondroitin sulfate

    go.drugbank.com/drugs/DB09301
    ApprovedInvestigationalNutraceutical

    Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, a...

  4. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  5. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and

  6. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies

  7. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  8. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

  9. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

  10. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732